Copyright
©The Author(s) 2023.
World J Gastroenterol. Mar 21, 2023; 29(11): 1745-1756
Published online Mar 21, 2023. doi: 10.3748/wjg.v29.i11.1745
Published online Mar 21, 2023. doi: 10.3748/wjg.v29.i11.1745
Ref. | Patients, n | Study period in yr | Pre-LT | Post-LT | ||||||||
Liver disease | CD4(+) T cell count as cells/μL | HIV-RNA as copies/mm3 | HBV-DNA as IU/mL | Median follow-up in mo | Latest CD4(+) T cell count as cells/μL | Latest HIV-RNA as copies/mm3 | Latest HBV-DNA as IU/mL | Rejections, n | Survival after LT in mo | |||
Tateo et al[12] | 13 | 1999-2007 | HBV | 173 (118-615)1 | 100% < 40 | 100% < 12 | 32 ± 5.22 | 281 (10-810)1 | 100% < 40 | 100% < 12 | 2 | 100% 1 yr, 100% 3 yr, 100% 5 yr |
Schreibman et al[27] | 6 | 1999-2006 | 5 HBV, 1 ALF | 100% > 100 | 100% < 200 | 66.7% < 12 | 60 (2-64)1 | 83.3% > 100 | 100% < 100 | 83.3% ND | 1 | 66.7% 1 yr, 66.7% 3 yr, 66.7% 5 yr |
Norris et al[25] | 5 | 1995-2003 | 4 HBV, 1 ALF | 187 (124-293)1 | 20% < 50 | 100% < 12 | 15 (6-65)1 | 467 (241-754)1 | 100% < 50 | 100% < 12 | 1 | 100% 1 yr, 100% 3 yr |
Coffin et al[15] | 22 | 2001-2007 | 21 HBV, 1 ALF | 317 (38–1070)1 | 100% < 40 | 45.4% ND | 42 (0.6-84)1 | 289 (48–744)1 | NA | 68% ND | 5 | 85% 1 yr, 85% 3 yr |
Vernadakis et al[1] | 2 | 1996-2009 | 1 HBV, 1 ALF | 219, 403 | 50% < 50 | NA | 3, 34 | NA | NA | NA | 0 | 3, 34 |
Neff et al[22] | 4 | 1997-2001 | 2 HBV, 2 ALF | 75% > 100 | 50% < 50 | ND | 21 (5-36)1 | 100% > 100 | 100% < 50 | ND | 3 | 100% 1 yr, 100% 3 yr |
Anadol et al[23] | 10 | 1997-2011 | HBV | 100% > 100 | 80% < 50 | ND | NA | NA | ND | ND | 1 | 80% 1 yr, 80% 3 yr, 80% 5 yr |
Radecke et al[24] | 1 | 1998-2001 | HBV | 196 | 380 | NA | 3 | > 100 | NA | NA | 1 | 3 |
Schliefer et al[26] | 1 | 1997-1999 | ALF | 477 | < 80 | NA | 27 | > 100 | < 80 | NA | 0 | 27 (Alive) |
Roland et al[21] | 1 | NA | HBV | 439 | ND | ND | 20 | 305 to 700 | ND | ND | 0 | 20 (Alive) |
Terrault et al[1] | 4 | 2000-2002 | HBV | 175 (104-439) | 100% < 75 | ND | 18, 25, 42, 48 | 315 (125-505) | ND | ND | 0 | 100% 1 yr, 100% 3 yr |
- Citation: Tang JX, Zhang KJ, Fang TS, Weng RH, Liang ZM, Yan X, Jin X, Xie LJ, Zeng XC, Zhao D. Outcomes of ABO-incompatible liver transplantation in end-stage liver disease patients co-infected with hepatitis B and human immunodeficiency virus. World J Gastroenterol 2023; 29(11): 1745-1756
- URL: https://www.wjgnet.com/1007-9327/full/v29/i11/1745.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i11.1745